Transmyocardial laser revascularization

Area of Science:

• Cardiovascular Surgery
• Minimally Invasive Procedures
• Laser Technology in Medicine

Background:

• Transmyocardial laser revascularization (TMR) evolved from early attempts in the 1980s using low-powered lasers as an adjunct to coronary artery bypass graft surgery (CABG).
• High-powered lasers, introduced in 1990, enable TMR to create transmyocardial channels with reduced thermal damage, making it suitable for patients with severe, diffuse coronary artery disease (CAD) and refractory angina.

Purpose of the Study:

• To review the background of transmyocardial laser revascularization (TMR).
• To analyze recently published randomized studies on TMR.
• To discuss the current understanding and remaining questions regarding TMR's mechanism of action.

Main Methods:

• Review of historical data on laser use in cardiac surgery.
• Analysis of clinical studies evaluating TMR as a sole operative therapy for severe CAD.
• Examination of results from four controlled randomized studies comparing TMR outcomes.
• Assessment of data supporting FDA approval for TMR laser systems.

Main Results:

• TMR is FDA-approved as a sole therapy for specific patient populations with severe CAD and angina.
• Four controlled randomized studies have been published, with data from two forming the basis for FDA approval.
• Despite clinical application and approval, the precise mechanism of action for TMR remains unclear.

Conclusions:

• Transmyocardial laser revascularization (TMR) is an established therapy for select patients with severe coronary artery disease (CAD).
• Further research is needed to elucidate the underlying mechanism of action of TMR.
• Ongoing studies are investigating the efficacy of combined TMR and CABG procedures.